Gyre Therapeutics, Inc. (NASDAQ:GYRE) reported a series of transactions by a key executive, according to a recent SEC filing. Usman Nassim, a director of the company, engaged in both acquisition and disposal of company shares on May 1, 2024.
Nassim acquired 20,000 shares of Gyre Therapeutics' common stock at $6.93 each, totaling $138,600. On the same day, he sold a total of 20,000 shares at varying prices. The first sale of 14,900 shares was at a weighted average price of $13.86, with individual sales ranging from $13.50 to $14.44. The second transaction involved 5,000 shares sold at an average price of $14.90, with prices stretching from $14.50 to $15.32. The final sale of 100 shares was at $15.63 per share. The combined sales amounted to over $282,577.
These sales were conducted under a pre-arranged 10b5-1 trading plan, which allows company insiders to sell shares at predetermined times to avoid accusations of insider trading.
The transactions have resulted in Nassim's direct ownership of 1,636 shares of common stock, in addition to indirect ownership of 563 shares by The Usman Family Trust and 77 shares by Nassim Usman IRA.
This recent filing provides transparency into the trading activities of Gyre Therapeutics' insiders and allows investors to stay informed on the moves of key company figures.
InvestingPro Insights
In light of the recent insider transactions at Gyre Therapeutics, Inc. (NASDAQ:GYRE), it's beneficial for investors to consider the broader financial landscape of the company. According to real-time data from InvestingPro, Gyre Therapeutics has a market capitalization of $1.21 billion. Despite a challenging short-term performance with a one-week price total return of -15.13% and a one-month price total return of -18.42%, the company has demonstrated resilience over the longer term, boasting a one-year price total return of 105.94%.
The company's financial health is reflected in its gross profit margin, which stands at an impressive 95.91% for the last twelve months as of Q4 2023, indicating efficient management of production costs relative to sales. Furthermore, the EBITDA growth for the same period is notably high at 96.74%, suggesting substantial operational profitability and potential for future growth.
When considering the recent insider trading, two InvestingPro Tips offer additional context: First, Gyre Therapeutics has been trading at a high EBITDA valuation multiple, which could indicate that the market has high expectations for the company's future earnings potential. Second, the company's liquid assets exceed its short-term obligations, providing a cushion for operational needs or potential investments.
For investors looking for a deeper dive into Gyre Therapeutics' financials and insider activities, InvestingPro provides a range of additional tips to help make informed decisions. As of now, there are 11 more InvestingPro Tips available, which can be accessed through the company-specific page at https://www.investing.com/pro/GYRE. To enhance your investing strategy with these insights, use coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.